Markets:

Overview

News

Currencies

International

Treasuries

Acumen Pharmaceuticals, Inc. - Common Stock (NQ:ABOS)

1.708 -0.022 (-1.25%)

Streaming Delayed Price Updated: 11:19 AM EST, Nov 17, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Acumen Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 Next >

Acumen Pharmaceuticals Inc (NASDAQ:ABOS) Reports Q3 2025 Earnings, Beats EPS Estimates ↗

November 12, 2025

Acumen Pharmaceuticals posts better-than-expected Q3 2025 results, advancing its Alzheimer's treatment pipeline with cash into 2027.

Via Chartmill

Topics Earnings

Earnings Scheduled For November 12, 2025 ↗

November 12, 2025

Via Benzinga

Preview: Acumen Pharmaceuticals's Earnings ↗

November 11, 2025

Via Benzinga

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

September 25, 2025

Gainers PepGen (NASDAQ: PEPG) stock rose 114.3% to $5.7 during Thursday's regular session. The market value of their outstanding shares is at $87.2 million.

Via Benzinga

Acumen Pharmaceuticals's Earnings: A Preview ↗

August 11, 2025

Via Benzinga

A Preview Of Acumen Pharmaceuticals's Earnings ↗

May 12, 2025

Via Benzinga

Preview: Acumen Pharmaceuticals's Earnings ↗

March 26, 2025

Via Benzinga

Earnings Scheduled For November 12, 2024 ↗

November 12, 2024

Via Benzinga

Acumen Pharmaceuticals Earnings Preview ↗

November 11, 2024

Via Benzinga

Acumen Pharmaceuticals's Earnings: A Preview ↗

March 25, 2024

Via Benzinga

Earnings Scheduled For August 12, 2025 ↗

August 12, 2025

Via Benzinga

Earnings Scheduled For May 13, 2025 ↗

May 13, 2025

Via Benzinga

Tesla To $345? Here Are 10 Top Analyst Forecasts For Friday ↗

March 28, 2025

Via Benzinga

Earnings Scheduled For March 27, 2025 ↗

March 27, 2025

Via Benzinga

Acumen Pharmaceuticals's Earnings Outlook ↗

November 10, 2023

Via Benzinga

Acumen Pharmaceuticals's Earnings: A Preview ↗

August 07, 2023

Via Benzinga

ABOS Stock Earnings: Acumen Pharmaceuticals Misses EPS for Q2 2024 ↗

August 13, 2024

ABOS stock results show that Acumen Pharmaceuticals missed analyst estimates for earnings per share the second quarter of 2024.

Via InvestorPlace

Trading SMID Biotech Stocks In A Volatile Market ↗

July 01, 2024

Trading SMID biotech stocks is difficult no matter what you know. Large cap biopharma with dividends should be the focus for non-traders. Healthcare and smaller caps are lagging within the context of a...

Via Talk Markets

ABOS Stock Earnings: Acumen Pharmaceuticals Beats EPS for Q1 2024 ↗

May 14, 2024

ABOS stock results show that Acumen Pharmaceuticals beat analyst estimates for earnings per share the first quarter of 2024.

Via InvestorPlace

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

May 14, 2024

Via Benzinga

ABOS Stock Earnings: Acumen Pharmaceuticals Misses EPS for Q4 2023 ↗

March 26, 2024

ABOS stock results show that Acumen Pharmaceuticals missed analyst estimates for earnings per share the fourth quarter of 2023.

Via InvestorPlace

Earnings Scheduled For March 26, 2024 ↗

March 26, 2024

Companies Reporting Before The Bell • bluebird bio (NASDAQ:BLUE) is likely to report quarterly loss at $0.66 per share on revenue of $16.68 million.

Via Benzinga

Buy Alert: 3 Healthcare Stocks Sitting in the Sweet Spot ↗

January 30, 2024

Healthcare stocks to buy are not talked about as much right now, but are great stocks investors should consider adding.

Via InvestorPlace

3 Healthcare Stocks to Buy as the Sector Benefits from the Aging Boom ↗

January 24, 2024

These three aging stocks offer different thematic approaches to profit from the opportunities that exist in an aging population.

Via InvestorPlace

Are You A Trader Or Investor: Biotech Momentum Is Picking Up ↗

November 20, 2023

ETFs have not helped as portfolio fillers but they can identify trends. We should play this rally out of a biotech bear market.

Via Talk Markets

Topics ETFs

Quest For Alzheimer's Cure: Big Biotech Breakthroughs, But The Race Is Just Beginning ↗

November 17, 2023

Biotech companies are edging closer to finding the answers behind Alzheimer's disease.

Via Investor's Business Daily

Under the Microscope: 3 Biotech Stocks Pioneering Tomorrow’s Cures ↗

November 09, 2023

Unveil the resilience of biotech stocks as they outsmart market trends and champion the race for tomorrow's treatments.

Via InvestorPlace

3 Promising Biotech Stocks Flying Under the Radar ↗

November 08, 2023

Breakthroughs in healthcare are happening everyday, make sure you are keeping up to date on these under the radar biotech stocks.

Via InvestorPlace

Upcoming Phase 2 Data Expected For Longeveron's (NASDAQ: LGVN) Drug For the $4+ Billion Alzheimer's Sector – What To Look For ↗

September 06, 2023

Longeveron (NASDAQ: LGVN), a clinical-stage biopharma developing potential treatments for age-related and life-threatening diseases, is expecting data from its phase 2a trial for its Lomecel-B™...

Via Benzinga

Earnings Scheduled For November 13, 2023 ↗

November 13, 2023

Companies Reporting Before The Bell • Sohu.com (NASDAQ:SOHU) is expected to report earnings for its third quarter. • Dixie Gr (NASDAQ:DXYN) is estimated to report earnings for its third quarter.

Via Benzinga

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Acumen Pharmaceuticals, Inc. - Common Stock (NQ:ABOS)

Headline News about Acumen Pharmaceuticals, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today